Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
The AnaCardio R&D AB patent portfolio is situated within the Biotechnology & Pharmaceuticals technology area. At present, the portfolio's prosecution history is characterized by a focused alignment, involving 1 distinct examiner and 1 distinct art unit. This structure suggests a specific technological focus for the current filings within the pharmaceutical industry.
STEELE, AMBER D is the busiest examiner associated with these records. This examiner is currently managing 1 busiest examiner pending office action. This specific task accounts for the entirety of the 1 pending office actions currently facing the portfolio.
The use of 1 distinct art unit indicates that the prosecution is not fragmented across different regulatory groups. For a practitioner, this means that the 1 pending office action is the focus of current administrative efforts. Navigating the Biotechnology & Pharmaceuticals requirements with STEELE, AMBER D will be the path toward advancing the portfolio's status. The concentration in 1 distinct art unit ensures that the examiner is likely a specialist in the relevant technology.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEELE, AMBER D | 1 | 58.9% | +9.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17757350 | TREATMENT OF ACUTE HEART FAILURE | STEELE, AMBER D | 78d |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17757350 | TREATMENT OF ACUTE HEART FAILURE | STEELE, AMBER D | 1627 | §101§102§112 | Non-Final OA | 78d | Pending | Jun 14, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial